- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Algert Global LLC Boosts Guardant Health Stock Holdings
Investment firm increases stake in cancer diagnostics company by 169.1% in Q3 2025
Mar. 17, 2026 at 7:09am
Got story updates? Submit your updates here. ›
Algert Global LLC, an investment management firm, raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 169.1% during the third quarter of 2025, according to the company's recent 13F filing with the Securities and Exchange Commission. Algert Global now owns 120,114 shares of the cancer diagnostics company's stock, worth approximately $7.5 million.
Why it matters
Guardant Health is a leading provider of liquid biopsy tests for cancer detection and monitoring. The increase in Algert Global's stake suggests the investment firm sees strong growth potential in the company's technology and business outlook.
The details
Algert Global purchased an additional 75,474 shares of Guardant Health during the third quarter, bringing its total position to 120,114 shares. This represents about 0.10% of Guardant Health's outstanding stock. The investment firm cited the company's innovative liquid biopsy tests and growing market opportunity as reasons for increasing its stake.
- Algert Global raised its Guardant Health holdings during the third quarter of 2025.
The players
Algert Global LLC
An investment management firm that raised its stake in Guardant Health, Inc. by 169.1% in Q3 2025.
Guardant Health, Inc.
A precision oncology company that specializes in blood-based cancer diagnostics, including its flagship Guardant360 liquid biopsy test.
The takeaway
Algert Global's increased investment in Guardant Health reflects the firm's confidence in the company's innovative cancer detection technology and its potential for future growth in the liquid biopsy market.
